E-Health in Germany: Three New Laws Signify the Imminent Transformation to a Digitalised Healthcare System

The Opportunity for Real-World Data and Evidence in Ophthalmology

Amazon’s Healthcare Strategy Hinges on Data

E-Health in Germany: Rapid Progression of Digitalisation?

Disease Management Programs (DMPs) in Germany: The Importance of Guideline Inclusion for Chronic Therapies

Putting Cerner’s Big Investment in Lumeris Into Strategic Context

Scaling the Mountain: Adoption Strategy for Digital Health

Three Models for Population Health Technology

Seattle’s Journey to the Summit of Cancer Commercialization

The Accelerated Access Review in the UK: Quicker Access to Innovative Drugs and Diagnostics, Medical and Digital Technologies

Why Flatiron’s Big Exit May Not Be the Boon for Digital Health That Some Expect

PART 3: What’s Next in 2018? Advanced Therapeutics – Gene Therapy, CAR-T, and Microbiome

PART 2: 2018 Wildcards – Healthcare Regulation and Models of Care

Who’s Really First in FDA Cleared Digital Therapeutics?

New Digital Health Solutions are Hot; but Success is Still Grounded in Fundamental Rules of Commercialization

Envisioning the Future of Digital Health

Market Forces Begin to Cut Through the Hype on Mobile Health Tech

How Much Longer Before Biopharma Embraces Remote Monitoring in Clinical Trials?

Don’t Fire Your Doctor…Yet

Health Advances at ADA: Industry Forum Panel “Embracing the Future of Open Data Sharing”

Health Advances Blog

Category: Health IT and Digital Health

E-Health in Germany: Three New Laws Signify the Imminent Transformation to a Digitalised Healthcare System

The Opportunity for Real-World Data and Evidence in Ophthalmology

Amazon’s Healthcare Strategy Hinges on Data

E-Health in Germany: Rapid Progression of Digitalisation?

Disease Management Programs (DMPs) in Germany: The Importance of Guideline Inclusion for Chronic Therapies

Putting Cerner’s Big Investment in Lumeris Into Strategic Context

Scaling the Mountain: Adoption Strategy for Digital Health

Three Models for Population Health Technology

Seattle’s Journey to the Summit of Cancer Commercialization

The Accelerated Access Review in the UK: Quicker Access to Innovative Drugs and Diagnostics, Medical and Digital Technologies

Why Flatiron’s Big Exit May Not Be the Boon for Digital Health That Some Expect

PART 3: What’s Next in 2018? Advanced Therapeutics – Gene Therapy, CAR-T, and Microbiome

PART 2: 2018 Wildcards – Healthcare Regulation and Models of Care

Who’s Really First in FDA Cleared Digital Therapeutics?

New Digital Health Solutions are Hot; but Success is Still Grounded in Fundamental Rules of Commercialization

Envisioning the Future of Digital Health

Market Forces Begin to Cut Through the Hype on Mobile Health Tech

How Much Longer Before Biopharma Embraces Remote Monitoring in Clinical Trials?

Don’t Fire Your Doctor…Yet

Health Advances at ADA: Industry Forum Panel “Embracing the Future of Open Data Sharing”